We are live on
!
Find out more
PA
PharVision Advisers Portfolio holdings
AUM
$9.86M
1-Year Est. Return
9.93%
This Fund
S&P 500
This Quarter
Est. Return
+0.93%
1 Year Est. Return
+9.93%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$198M
AUM Growth
+$19.8M
(+11%)
Cap. Flow
+$23.3M
Cap. Flow
% of AUM
11.78%
Top 10 Holdings %
Top 10 Hldgs %
3.45%
Holding
1,063
New
409
Increased
141
Reduced
117
Closed
396
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Delek US
DK
|
+$871K |
| 2 |
Broadcom
AVGO
|
+$691K |
| 3 |
Agilent Technologies
A
|
+$650K |
| 4 |
Telos
TLS
|
+$640K |
| 5 |
Pagaya Technologies
PGY
|
+$627K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Array Technologies
ARRY
|
+$730K |
| 2 |
Vertiv
VRT
|
+$639K |
| 3 |
Zevra Therapeutics
ZVRA
|
+$635K |
| 4 |
BOW
Bowhead Specialty Holdings
BOW
|
+$608K |
| 5 |
Rigel Pharmaceuticals
RIGL
|
+$581K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.19% |
| 2 | Industrials | 15.13% |
| 3 | Financials | 12.4% |
| 4 | Consumer Discretionary | 11.79% |
| 5 | Healthcare | 11.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1026
VinFast Auto
VFS
$6.9B
| – | – |
-13,473
| Closed | -$43.4K |
|
1027
Viemed Healthcare
VMD
$470M
| – | – |
-39,036
| Closed | -$265K |
|
1028
Vanda Pharmaceuticals
VNDA
$313M
| – | – |
-57,037
| Closed | -$285K |
|
1029
Varex Imaging
VREX
$470M
| – | – |
-32,142
| Closed | -$399K |
|
|
1030
Vertiv
VRT
$105B
| – | – |
-4,238
| Closed | -$639K |
|
1031
Vishay Intertechnology
VSH
$5.36B
| – | – |
-15,529
| Closed | -$238K |
|
1032
Verizon
VZ
$202B
| – | – |
-4,822
| Closed | -$212K |
|
1033
GeneDx Holdings
WGS
$1.78B
| – | – |
-1,879
| Closed | -$202K |
|
1034
Williams Companies
WMB
$86.4B
| – | – |
-3,977
| Closed | -$252K |
|
1035
Worthington Enterprises
WOR
$2.8B
| – | – |
-5,753
| Closed | -$319K |
|
1036
WSFS Financial
WSFS
$4.16B
| – | – |
-4,276
| Closed | -$231K |
|
1037
Western Union
WU
$2.59B
| – | – |
-13,291
| Closed | -$106K |
|
1038
Wolverine World Wide
WWW
$1.59B
| – | – |
-7,691
| Closed | -$211K |
|
1039
Wynn Resorts
WYNN
$10.4B
| – | – |
-1,703
| Closed | -$218K |
|
1040
XPeng
XPEV
$12.1B
| – | – |
-11,585
| Closed | -$271K |
|
1041
Expro Ltd
XPRO
$1.76B
| – | – |
-12,775
| Closed | -$152K |
|
1042
Dentsply Sirona
XRAY
$2.64B
| – | – |
-29,526
| Closed | -$375K |
|
1043
Yum China
YUMC
$15.7B
| – | – |
-6,393
| Closed | -$274K |
|
1044
Zebra Technologies
ZBRA
$12.5B
| – | – |
-727
| Closed | -$216K |
|
1045
Zegna
ZGN
$3.99B
| – | – |
-14,987
| Closed | -$142K |
|
1046
ZIM Integrated Shipping Services
ZIM
$2.94B
| – | – |
-15,018
| Closed | -$203K |
|
1047
Zoom
ZM
$26.8B
| – | – |
-4,144
| Closed | -$342K |
|
1048
Zscaler
ZS
$23.9B
| – | – |
-740
| Closed | -$222K |
|
|
1049
Zevra Therapeutics
ZVRA
$578M
| – | – |
-66,733
| Closed | -$635K |
|
1050
Zymeworks
ZYME
$1.73B
| – | – |
-17,790
| Closed | -$304K |
|
Similar funds
BS
RG
MP
CCM
DFA
CCP
FRT
VH
PharVision Advisers's Q4 2025 Portfolio in Review
As of Q4 2025, PharVision Advisers held 1,063 positions worth $198M, up 11% from $178M the previous quarter. Its ten largest holdings account for 3.5% of the portfolio.
PharVision Advisers deployed $23.3M of net new capital in Q4 2025, opening 409 new positions and adding to 141 existing holdings. Its largest new stake was Delek US: 24,407 shares worth $724K.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 15% a quarter earlier, followed by Industrials and Financials.
On the sell side, the largest reduction was Wayfair, an estimated $510K trimmed.
- PharVision Advisers's largest Q4 2025 buy was Delek US: 24,407 shares worth $724K.
- PharVision Advisers added most to NIO in Q4 2025, an estimated $557K increase.
- PharVision Advisers's biggest Q4 2025 reduction was Wayfair, cutting an estimated $510K.
- PharVision Advisers fully exited Array Technologies in Q4 2025, selling an estimated $730K.
- PharVision Advisers's ten largest holdings make up 3.5% of its $198M portfolio in Q4 2025.
- PharVision Advisers opened 409 new positions and closed 396 in Q4 2025.
- PharVision Advisers's portfolio value rose 11% quarter-over-quarter to $198M.
Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.